Literature DB >> 16546928

Glucan and glutamine reduce bacterial translocation in rats subjected to intestinal ischemia-reperfusion.

Aldo Cunha Medeiros1, Dâmaso Araújo Chacon, Valéria Soraya Farias Sales, Eryvaldo Sócrates Tabosa Egito, José Brandão-Neto, Laíza Araújo Mohana Pinheiro, Mariana Rego Carvalho.   

Abstract

Intestinal ischemia/reperfusion (I/R) may induce bacterial translocation (BT). Glutamine (GLN)-enriched nutrition decreases BT. However, little is known about the effect of glucan (GL) in BT. This study investigated the combined effect of GL/GLN on BT, intestinal damage, and portal blood cytokines in animals under I/R. Four groups of 10 rats each were subjected to 60 min of intestinal ischemia and 120 min of reperfusion. The control group (group 1) received only rat food/water, group 2 received glutamine via gavage, group 3 received subcutaneuos soluble (1, 3)-d-glucan, and group 4 received GL + GLN. A sham group (group 5) served as a normal control. Bacterial cultures of ileum, mesenteric lymph nodes (MLN), liver and lung biopsies, histological changes of ileum, and serum cytokines variables were examined after I/R. Data were analyzed by analysis of variance (ANOVA) and the Newman-Keuls test. Results showed that GLN, GL, and GL/GLN significantly reduced BT to MLN, liver, and lung. BT was more attenuated after GL treatment than GLN (P < .05). Rats treated with both GL and GLN exhibited lower bacterial colony counts than the ones treated only with GLN or GL. Severe mucosal damage on histological findings was shown in group 1, but these findings were significantly ameliorated (P < .05) in groups 3 and 4. Tumor necrosis factor (TNF)-a and interleukin (IL)-6 levels in portal serum were significantly reduced and IL-10 was increased by GL and GLN treatment. In conclusion, the use of GL was more effective than GLN in reducing BT, intestinal damage, and cytokine levels after I/R. Additionally, the combination of GL and GLN improved results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546928     DOI: 10.1080/08941930500444453

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  6 in total

1.  Enteral glutamine pretreatment does not decrease plasma endotoxin level induced by ischemia-reperfusion injury in rats.

Authors:  Arda Demirkan; Erkin Orazakunov; Berna Savaş; M Ayhan Kuzu; Mehmet Melli
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

2.  Glutamine protects against apoptosis via downregulation of Sp3 in intestinal epithelial cells.

Authors:  Kechen Ban; Rosemary A Kozar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-09-30       Impact factor: 4.052

Review 3.  The role of intestinal microbiota and its metabolites in intestinal and extraintestinal organ injury induced by intestinal ischemia reperfusion injury.

Authors:  Fan Deng; Ze-Bin Lin; Qi-Shun Sun; Yue Min; Yue Zhang; Yu Chen; Wen-Ting Chen; Jing-Juan Hu; Ke-Xuan Liu
Journal:  Int J Biol Sci       Date:  2022-06-13       Impact factor: 10.750

4.  Distinct cytoprotective roles of pyruvate and ATP by glucose metabolism on epithelial necroptosis and crypt proliferation in ischaemic gut.

Authors:  Ching-Ying Huang; Wei-Ting Kuo; Chung-Yen Huang; Tsung-Chun Lee; Chin-Tin Chen; Wei-Hao Peng; Kuo-Shyan Lu; Chung-Yi Yang; Linda Chia-Hui Yu
Journal:  J Physiol       Date:  2016-06-17       Impact factor: 5.182

5.  Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat.

Authors:  Fangming Zhang; Rongqian Wu; Mian Zhou; Steven A Blau; Ping Wang
Journal:  Regul Pept       Date:  2008-10-07

6.  Protective effects of pentoxifylline in small intestine after ischemia-reperfusion.

Authors:  Seracettin Eğin; Mehmet İlhan; Süleyman Bademler; Berk Gökçek; Semih Hot; Hakan Ekmekçi; Özlem Balcı Ekmekçi; Gamze Tanrıverdi; Fatma Kaya Dağıstanlı; Gülçin Kamalı; Sedat Kamalı; Recep Güloğlu
Journal:  J Int Med Res       Date:  2018-07-20       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.